Products for Research Use Only
RegisterLogin

Siponimod (hemifumarate)

CAT: 0804-HY-12355ASize: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-12355ASize:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively) . Siponimod hemifumarate can be used for multiple sclerosis (MS) research[1][2].
CAS Number
1234627-85-0
Product Name Alternative
BAF-312 (hemifumarate)
UNSPSC
12352005
Hazard Statement
H361, H373, H411
Target
LPL Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/siponimod-hemifumarate.html
Purity
99.64
Solubility
DMSO : 12.5 mg/mL (ultrasonic)
Smiles
O=C(C1CN(CC2=CC=C(/C(C)=N/OCC3=CC=C(C4CCCCC4)C(C(F)(F)F)=C3)C=C2CC)C1)O.OC(/C=C/C(O)=O)=O.[1/2]
Molecular Formula
C29H35F3N2O3.1/2C4H4O4
Molecular Weight
574.63
Precautions
H361, H373, H411
References & Citations
[1]Pan S, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4 (3) :333-7.|[2]McGinley M, et al. Prospects of siponimod in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2018 Jul 17;11:1756286418788013.|[3]Behrangi N, et al. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019 Jan 7;8 (1) :24.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
S1PR1; S1PR2; S1PR3; S1PR4; S1PR5

Chemical Information

Siponimod Fumarate

Siponimod Fumarate is the fumarate salt form of siponimod, an orally bioavailable sphingosine 1-phosphate (S1P) receptor modulator, with potential anti-inflammatory and immunomodulating activities. Upon oral administration, siponimod targets and binds to S1P receptors 1 and 5 on lymphocytes. This prevents the egress of lymphocytes from lymph nodes, thereby reducing both the number of circulating peripheral lymphocytes and the infiltration of lymphocytes into target tissues, such as the central nervous system (CNS). This prevents lymphocyte-mediated immune response and may reduce inflammation. S1P plays a key role in lymphocyte migration from lymphoid tissues. Siponimod does not target S1P receptor 3, the activation of which may be responsible for adverse effects such as bradycardia associated with other S1P receptor modulators.

CAS Number1234627-85-0
PubChem CID46700777
IUPAC Name(E)-but-2-enedioic acid;bis(1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid)
Molecular FormulaC62H74F6N4O10
Molecular Weight1149.3
Topological Polar Surface Area199
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count20
Rotatable Bond Count20
Heavy Atom Count82
Formal Charge0
Complexity896
SMILES
CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O.CCC1=C(C=CC(=C1)/C(=N/OCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)/C)CN4CC(C4)C(=O)O.C(=C/C(=O)O)\C(=O)O
InChI
InChI=1S/2C29H35F3N2O3.C4H4O4/c2*1-3-21-14-23(10-11-24(21)15-34-16-25(17-34)28(35)36)19(2)33-37-18-20-9-12-26(22-7-5-4-6-8-22)27(13-20)29(30,31)32;5-3(6)1-2-4(7)8/h2*9-14,22,25H,3-8,15-18H2,1-2H3,(H,35,36);1-2H,(H,5,6)(H,7,8)/b2*33-19+;2-1+
InChIKey
JNLIKIBISICTMS-PEJBKAKVSA-N
Chemical Structure
2D Structure
2D structure of Siponimod Fumarate
CAS: 1234627-85-0
CID: 46700777
Formula: C62H74F6N4O10
MW: 1149.3
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight1149.3
Hydrogen Bond Donor Count4
Hydrogen Bond Acceptor Count20
Rotatable Bond Count20
Exact Mass1148.53091354
Monoisotopic Mass1148.53091354
Topological Polar Surface Area199 Ų
Heavy Atom Count82
Formal Charge0
Complexity896
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count3
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count3
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-12355-01Siponimod
HY-12355SSiponimod-d11
HY-12355R-01Siponimod (Standard)
HY-12177-01Aliskiren (hemifumarate)
HY-19578BIsamoltane (hemifumarate)
HY-B0031-01Quetiapine (hemifumarate)
HY-103540-01Tabimorelin (hemifumarate)
HY-101327A-01Xamoterol (hemifumarate)
HY-13064A-01Cobimetinib (hemifumarate)
HY-100490A-01Rilmenidine (hemifumarate)

Alternative Products

CatalogName
GTR19185446-01Siponimod hemifumarate
206455Siponimod
S7179-25mgSiponimod (BAF312)
AR-S10437-01Siponimod Trifluoroacetate
B3225-100BAF312 (Siponimod)
CS-EO-02968Siponimod-d5
CS-CX-00610Siponimod D11
AR-S10418-01Siponimod Dimer
AR-S10421-01(Z) -Siponimod

Popular Products